Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx™ in paraffin-embedded cancer tissues
Authors:
- 1 December 2006
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 12 (4) , 243-246
Abstract
EGF receptor (EGFR) became a useful target for several recently introduced therapies of various cancer types including colorectal, lung, head and neck cancers and glioblastoma. The successful clinical application of these novel molecularly targeted therapies requires the expression of their target, EGFR, determined by nucleic acid based or immunohistochemical techniques. However, until now, immunohistochemistry has not become a reliable diagnostic approach for this purpose. The golden standard for the determination of EGFR protein expression in paraffin-embedded cancer tissues is the EGFR pharmDx™ kit. Here we show that the recommended protocol may not be optimal for EGFR immunodetection. Microwave antigen retrieval and extended primary antibody incubation time converted four out of eight EGFR-negative tumors into EGFR-positive in a study of 50 lung adenocarcinoma cases. Accordingly, we recommend retesting cases negative for EGFR with EGFR pharmDx™ using protocol modifications optimizing antigen retrieval and the incubation periods.Keywords
This publication has 9 references indexed in Scilit:
- Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor TherapyClinical Cancer Research, 2006
- Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in CancerJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: It's Time to Get Back on TargetJournal of Clinical Oncology, 2005
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryJournal of Clinical Oncology, 2005
- Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrowCancer Cell, 2004
- Searching for Reliable Epidermal Growth Factor Receptor Response PredictorsClinical Cancer Research, 2004
- Expression of Epidermal Growth Factor Receptor in Invasive Transitional Cell Carcinoma of the Urinary Bladder:A Multivariate Survival AnalysisAmerican Journal of Clinical Pathology, 1994